32648017|t|Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naive and opioid-tolerant patients: a retrospective study.
32648017|a|PURPOSE: Tapentadol is a dual-acting mu-opioid receptor agonist and noradrenaline reuptake inhibitor with non-inferior analgesic efficacy to oxycodone and better gastrointestinal tolerability than full mu-opioid receptor agonists. Tapentadol is approved for cancer pain in Japan; however, real-world evidence on tapentadol's effectiveness and safety for cancer-related pain in Japan is limited. METHODS: This retrospective study evaluated the effectiveness, safety, and tolerability of tapentadol (by patient type-opioid-naive and opioid-tolerant) in 84 patients with moderate-to-severe cancer pain at Ichikawa General Hospital between September 2014 and August 2016. RESULTS: Almost 93% of patients achieved clinically relevant pain relief within 4 days (median). Over 90% of patients with neuropathic pain or mixed pain and all patients with nociceptive pain were responders. Pain intensity significantly decreased from baseline through to the end of maintenance period in opioid-naive and opioid-tolerant patients. No patients discontinued tapentadol due to serious adverse events. No opioid-naive patients experienced nausea or vomiting during tapentadol treatment. Only three opioid-tolerant patients experienced nausea which was considered to be related to tapentadol. CONCLUSION: Tapentadol is effective and well tolerated in opioid-naive and opioid-tolerant patients with cancer pain of varying pathophysiology, including those with nociceptive and/or neuropathic components. Tapentadol may be considered for first-line use in moderate-to-severe cancer-related pain.
32648017	0	10	Tapentadol	Chemical	MESH:D000077432
32648017	64	83	cancer-related pain	Disease	MESH:D000072716
32648017	120	128	patients	Species	9606
32648017	162	172	Tapentadol	Chemical	MESH:D000077432
32648017	221	253	noradrenaline reuptake inhibitor	Chemical	-
32648017	294	303	oxycodone	Chemical	MESH:D010098
32648017	384	394	Tapentadol	Chemical	MESH:D000077432
32648017	411	422	cancer pain	Disease	MESH:D000072716
32648017	465	475	tapentadol	Chemical	MESH:D000077432
32648017	507	526	cancer-related pain	Disease	MESH:D000072716
32648017	639	649	tapentadol	Chemical	MESH:D000077432
32648017	654	661	patient	Species	9606
32648017	707	715	patients	Species	9606
32648017	740	751	cancer pain	Disease	MESH:D000072716
32648017	844	852	patients	Species	9606
32648017	882	886	pain	Disease	MESH:D010146
32648017	930	938	patients	Species	9606
32648017	944	960	neuropathic pain	Disease	MESH:D009437
32648017	970	974	pain	Disease	MESH:D010146
32648017	983	991	patients	Species	9606
32648017	1009	1013	pain	Disease	MESH:D010146
32648017	1031	1035	Pain	Disease	MESH:D010146
32648017	1161	1169	patients	Species	9606
32648017	1174	1182	patients	Species	9606
32648017	1196	1206	tapentadol	Chemical	MESH:D000077432
32648017	1254	1262	patients	Species	9606
32648017	1275	1281	nausea	Disease	MESH:D009325
32648017	1285	1293	vomiting	Disease	MESH:D014839
32648017	1301	1311	tapentadol	Chemical	MESH:D000077432
32648017	1350	1358	patients	Species	9606
32648017	1371	1377	nausea	Disease	MESH:D009325
32648017	1416	1426	tapentadol	Chemical	MESH:D000077432
32648017	1440	1450	Tapentadol	Chemical	MESH:D000077432
32648017	1519	1527	patients	Species	9606
32648017	1533	1544	cancer pain	Disease	MESH:D000072716
32648017	1613	1624	neuropathic	Disease	MESH:D009437
32648017	1637	1647	Tapentadol	Chemical	MESH:D000077432
32648017	1707	1726	cancer-related pain	Disease	MESH:D000072716
32648017	Negative_Correlation	MESH:D000077432	MESH:D010146
32648017	Negative_Correlation	MESH:D000077432	MESH:D000072716
32648017	Positive_Correlation	MESH:D000077432	MESH:D009325
32648017	Comparison	MESH:D000077432	MESH:D010098
32648017	Negative_Correlation	MESH:D000077432	MESH:D009437

